METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease

Inclusion Criteria: * Chronic cardiac ischemic disease at least 4 months after one ore more myocardial infarctions in a stable phase of the disease without option for revascularization * LVEF at echocardiography ≤ 40% * Significant regional LV wall motion dysfunction in the infarct related territory * Symptoms NYHA II-IV or CCS II-III (at least class III according to one of the two classifications) * Patient agrees to comply with all follow-up evaluations * Age \> 18 years old * Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent Exclusion Criteria: * Abnormal regional wall motion outside the infarct region * Need for revascularization in a non infarct-related coronary within 6 months * Patient has moderate to severe aortic valve disease, aortic or mitral prosthetic valve * Patient has a significant mitral valve insufficiency (Effective Regurgitant office - ERO - \> 0.2 cm2 with possibility of mitral valve surgery * Left ventricular thrombus at echocardiography * LV-aneurysma planned surgical aneurysmectomy * LV-wall thickness \< 5mm in the target territory * Congenital heart disorder of hemodynamic relevance * Known active infection or chronic infection with HIV, HBV or HCV * Chronic inflammatory disease * Serious concomitant disease with a life expectancy of less than one year * Follow up impossible (no fixed abode, etc) * Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia) * Severe renal failure (creatinine \> 250 mmol/l) * Relevant liver disease (GOT \> 2x norm or spontaneous INR \> 1,5) * Anemia (Hb \< 8.5 mg/dl), Thrombocytopenia (\< 100.000/µl) * Women of child bearing potential or pregnancy * Participation at a clinical trial in the last 30 days